Tara Biosystems
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$300k | Seed | ||
$2.3m | Seed | ||
$9.0m | Series A | ||
N/A | N/A | Series A | |
$10.0m | Series A | ||
N/A | N/A | Series A | |
N/A | N/A | Series A | |
* | N/A | Acquisition | |
Total Funding | €19.6m |
Related Content
Recent News about Tara Biosystems
EditTARA Biosystems operates in the biotechnology sector, specializing in predictive cardiac models to enhance drug discovery and development for heart diseases. The company leverages a groundbreaking stem cell tissue engineering platform to create reproducible, functioning human heart tissue in the lab. This technology is trusted by over 30 pharmaceutical and biotechnology companies to predict clinical responses of new medicines for heart failure and other cardiac conditions. TARA's core clients include pharmaceutical companies, biotech firms, and research institutions focused on cardiac drug discovery and safety. The business model revolves around providing tailored solutions for each partner, ensuring that every project meets specific needs and objectives. TARA generates revenue through partnerships, research collaborations, and service contracts. The company operates in the global biotechnology market, focusing on precision cardiology and cardiac safety.
Keywords: predictive cardiac models, heart disease, drug discovery, stem cell engineering, pharmaceutical, biotechnology, heart tissue, clinical response, cardiac safety, precision cardiology.